GlassScriptPhysician profile
Eric J Areiter
NPI 1427496264
$13,063.56
in general payments reported to CMS, 2019-2025
18 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $280 · 2021: $220 · 2022: $321 · 2023: $1,188 · 2024: $269 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,000 · Food and Beverage: $3,547 · Debt Forgiveness: $297 · Travel and Lodging: $101 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,000.00 |
| Food and Beverage | $3,547.01 |
| Debt Forgiveness | $297.00 |
| Travel and Lodging | $100.76 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $8,301.83 | 2021-2025 | Travoprost Intraocular Implant - Idose, Idosetr, Istent Infinite |
| Rxsight INC | $2,074.72 | 2021-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Abbvie INC. | $605.13 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Sight Sciences, INC. | $445.69 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $357.04 | 2019-2021 | |
| Alcon Vision LLC | $323.11 | 2020-2025 | Clareon Panoptix Pro, Clareon, Hydrus Microstent |
| Biotissue Holdings INC. | $310.73 | 2021-2025 | |
| Optos, INC. | $297.00 | 2023 | Panoramic Ophthalmoscope |
| Novartis Pharmaceuticals Corporation | $68.02 | 2019-2023 | |
| Shire North American Group INC | $64.64 | 2019 | |
| Amgen INC. | $50.15 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $37.86 | 2019-2021 | |
| Harrow Eye, LLC | $28.50 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $21.47 | 2025 | Envista Envy Iol |
| Ocular Therapeutix, INC. | $20.74 | 2025 | Dextenza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $20.61 | 2023 | Syfovre |
| New World Medical,INC. | $20.20 | 2023 | |
| Horizon Therapeutics Plc | $16.12 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Areiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.